AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Piwi-like protein 2

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.

Our library is unique due to several crucial aspects:

  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

Q8TC59

UPID:

PIWL2_HUMAN

Alternative names:

Cancer/testis antigen 80

Alternative UPACC:

Q8TC59; A8K4S3; A8K8S5; B0AZN9; B0AZP2; B4DR22; E7ECA4; Q96SW6; Q9NW28

Background:

Piwi-like protein 2, also known as Cancer/testis antigen 80, plays a pivotal role in spermatogenesis by repressing transposable elements, crucial for germline integrity. It is instrumental in meiotic differentiation, germ cell differentiation, and spermatogonial stem cell self-renewal through the piRNA metabolic process. This process involves piRNA and Piwi protein complexes that govern transposon methylation and repression. Piwi-like protein 2 is key in piRNA biosynthesis, particularly in the ping-pong amplification cycle, acting as a 'slicer-competent' endoribonuclease.

Therapeutic significance:

Understanding the role of Piwi-like protein 2 could open doors to potential therapeutic strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.